Bolt Biotherapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Bolt Biotherapeutics focuses on BDC-3042 and BDC-4182 after discontinuing BDC-1001, reporting a net loss of $63.1 million for 2024.
NASDAQ
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company, released its 2023 annual report, highlighting progress in its clinical programs and financial position.